Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06104566 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Global Trial in APG2575 for Patients With CLL/SLL

StatusRecruiting
PhasePhase 3
Started
View on ClinicalTrials.gov ↗

Record History

  1. Primary completion date: Oct 20, 2025 to Dec 31, 2026 Study sites: 2 to 135 · Eligibility criteria shortened, about 2 wordsv6 Show 2 more changesShow less
    • Study sites: 2 to 135
    • Eligibility criteria shortened, about 2 words

    See this version in full on ClinicalTrials.gov ↗

  2. Study sites: 1 to 2v5
  3. Trial status: Not Yet Recruiting to Recruiting Study sites: 0 to 1v4 Show 1 more changeShow less
    • Study sites: 0 to 1
  4. Re-verified, no change to tracked fieldsv3
  5. Start date: Oct 20, 2023 to Dec 20, 2023 Eligibility criteria shortened, about 210 wordsv2 Show 1 more changeShow less
    • Eligibility criteria shortened, about 210 words

    See this version in full on ClinicalTrials.gov ↗

  6. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This is a global multicenter, open label, randomized, registrational phase III study to investigate the efficacy and safety of lisaftoclax in combination with BTK inhibitors in CLL/SLL patients who previously treated with BTK inhibitors
Trial Details
NCT Number NCT06104566
Lead Sponsor Ascentage Pharma Group Inc.
Conditions CLL/SLL
Enrollment 400 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov